• Transforming the UK’s clinical research processes.

  • Taking an innovative approach to regulation:

  • Accelerating deployment of new and existing treatments and technologies where there are system and patient benefits.

  • Life Sciences Recovery Roadmap Download the Recovery Roadmap for the life sciences sector here. The COVID-19 crisis has powerfully demonstrated the strategic importance of the life science sector to the UK’s health, security, and to the economy.

    The Life Sciences industry and charities have played a central role in tackling the COVID-19 pandemic. By creating new partnerships with the Government and NHS the sector has rapidly scaled up UK diagnostic capacity; supported the NHS to deliver care in a period of exceptional patient demand; and are leading the search for vaccinations and treatments to tackle the pandemic.
    We have also seen the future of healthcare in action. The scientific and technological revolution of the Life Sciences sector – from the use of AI and machine learning in R&D to the latest manufacturing technologies and new treatment paradigms – bringing real value to solving health challenges through new therapies and vaccines.

    The Life Sciences Recovery Roadmap sets out how the sector can work with the Government and the NHS so that the sector is at the heart of the economic recovery and can support the NHS in getting cutting edge healthcare to patients.

    This paper was submitted to Government by trade bodies that represent the life sciences and charity research sectors through the Life sciences COVID-19 Response Group, co-Chaired by Lord Bethell and Nadhim Zahawi MP.

    The Roadmap provides an overview of the critical issues affecting the sector as we look towards recovery and building a new partnership between the Life sciences sector, Government and NHS.
    The report focuses on six critical areas:

    • Transforming our partnership with the NHS to support delivery of the Long-Term Plan.

    • Developing a comprehensive strategy to improve UK manufacturing capability and supply chain resilience in medicines, medical devices and diagnostics.

    • Powering up the benefits of public and charity spending on medical research and delivering bold policies to incentivise research investment.
    Home3 2020-06-23T12:05:27+00:00
    Member’s Log-in

    EMIG Priorities

    Government needs to act now and present its vision for the sector post Brexit. This includes protecting the research ecosystem from uncertainty so that inward investment is not threatened, access  to the EU regulatory framework, preserving the single market for medicines and to facilitate access to the people skills that are essential to the delivery of medicines to patients in the UK.

    The European Medicines Agency (EMA) is currently responsible for Marketing Authorisations (MA) covering all 31 countries in Europe (including EEA countries). A MA submission for the UK alone will require the same level of company resource and will attract a lower priority in comparison. The UK could therefore be downgraded in the global launch sequence for new medicines. This would have negative consequences for patients, clinical research and the economy.

    The UK’s medical research charities play an increasingly important role to make the country an attractive place to invest. The members of the Association of Medical Research Charities (AMRC) fund £1.6bn worth of research per year and increasingly in a more strategic way involving commercial collaborations. For example, Myeloma UK has a number of such collaborations with more in the pipeline.

    The depth and breadth of world-class clinical science supported via the NIHR in England is enormous. It has pioneered successful new models of industry/academia/NHS collaboration such as the Translational Research Partnerships programme, and put in place several organisational measures to help industry navigate what is undoubtedly a complex environment.

    Stakeholders need to collaborate on measures to drive alignment between research programmes that generate data for market authorisation with the requirements of UK Health Technology Appraisals.

    A new UK value framework for better research should be developed.

    UK academics should be incentivised to design Innovative clinical trials in partnership with industry to generate UK-facing regulatory standard data.

    New flexible approaches to pricing and patient access schemes should be designed.

    The time between regulatory approval, HTA and adoption by the NHS should be shortened.

    {{options.title}}

    {{single.title}}

    {{single.start | moment( options.label_dateformat ? options.label_dateformat : 'dddd, MMMM D' ) }}

    {{single.excerpt}}

    {{remaining_years | leadingZero}}
    {{remaining_months | leadingZero}}
    {{remaining_days | leadingZero}}
    {{remaining_hours | leadingZero}}
    {{remaining_minutes | leadingZero}}
    {{remaining_seconds | leadingZero}}
    To become an EMIG Member click to find out how